The dermatology industry is approaching a critical new era. As competition heats up in atopic dermatitis and psoriasis, developers face increasing pressure to demonstrate significant differentiation, shorten development timelines, and uncover the next generation of high-value prospects beyond today's recognized targets and treatments.
The 10th Dermatology Drug Development Summit is the industry’s leading forum for furthering the discovery, development, and commercialization of novel treatments for inflammatory skin diseases.
The meeting, which brings together 90+ leaders from companies such as AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics, and others, covers discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions
This summit offers s a unique chance to benchmark emerging science, assess novel targets, and share practical lessons from across the dermatology pipeline.
Atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, epidermolysis bullosa, prurigo nodularis, and more are all covered in this year’s comprehensive program, which delves into the future of dermatology innovation.
Attendees will obtain practical insights into AI-enabled target discovery, translational de-risking, biomarker development, next-generation modalities, dosing optimization, clinical differentiation, and commercialization strategy through specialized discovery and preclinical, and clinical and commercial tracks.
Join the companies influencing dermatology’s future to find out where the next big market possibilities and innovative treatments will appear.
Explore the full agenda
- Explore 35+ sessions that address discovery, translational medicine, clinical development, commercialization, and investment strategies.
- Learn how leaders from AbbVie, Galderma, Eli Lilly, Merck, Rubedo, AOBiome, and other companies are developing next-generation dermatology pipelines.
- Discover new options for inflammatory, autoimmune, and uncommon dermatologic conditions.
- Preview the exclusive discovery & preclinical, and clinical & commercial tracks, which are designed to speed learning and networking.
- Benchmark the approach against the most recent thinking on AI-driven discovery, new targets, biomarker development, dosing optimization, and market differentiation.
About 10th Dermatology Drug Development Summit
The dermatology market is entering a pivotal new era. As competition intensifies across Atopic Dermatitis and Psoriasis, developers are under growing pressure to demonstrate meaningful differentiation, accelerate development timelines and identify the next generation of high-value opportunities beyond today's established targets and therapies.
The 10th Dermatology Drug Development Summit is the industry's premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease.
Bringing together 90+ leaders from the likes of AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics and more, spanning discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions, the meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets, and share practical lessons from across the dermatology pipeline.
This year's expanded program explores the future of dermatology innovation across Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Acne, Epidermolysis Bullosa, Prurigo Nodularis, and more.
With dedicated Discovery & Preclinical and Clinical & Commercial tracks, attendees will gain actionable insights into AI-enabled target discovery, translational de-risking, biomarker development, next-generation modalities, dosing optimization, clinical differentiation, and commercialization strategy.
Join the companies shaping the future of dermatology to discover where the next breakthrough therapies and the next major market opportunities will emerge.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.